Physician profile
Disleny Cruz
NPI 1013640226
$669.27
in general payments reported to CMS, 2019-2025
14 companies · $138 in 2025
The $138 reported for 2025 was more than what a typical Pediatrics, Critical Care provider received nationally (typical 2025 total: $80.91).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $353 · 2023: $178 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $315.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $149.52 | 2022-2023 | Briviact |
| Servier Pharmaceuticals LLC | $138.29 | 2025 | |
| Jazz Pharmaceuticals INC. | $123.36 | 2022-2023 | |
| Aquestive Therapeutics, INC. | $44.04 | 2022 | |
| Neurelis, INC. | $38.46 | 2022-2023 | Valtoco |
| Livanova USA, INC. | $36.94 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Azurity Pharmaceuticals, INC. | $22.42 | 2022 | |
| Biogen, INC. | $21.17 | 2023 | Spinraza |
| Immedica Pharma US, INC. | $20.32 | 2022 | |
| Ironshore Pharmaceuticals INC. | $16.05 | 2022 | |
| Eisai INC. | $15.69 | 2022 | |
| Sk Life Science, INC. | $15.20 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $14.70 | 2023 | Spritam |
| Takeda Pharmaceuticals U.S.A., INC. | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Disleny Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.